©The Author(s) 2026.
World J Gastroenterol. Feb 28, 2026; 32(8): 113861
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.113861
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.113861
Figure 3 Clinical course, timeline of events.
Local interventions such as yttrium-90 (Y-90) transarterial radioembolization are shown above the time bar. Liver area treated by Y-90 (if known) is indicated near each lightning bolt marking this intervention (R = right lobe, L = left lobe, Seg = segment). Both patients had no visible disease outside of liver when treated with Y-90 transarterial radioembolization. Results of clinical/ radiologic assessments are shown below the bar (green markers indicate favorable responses, while orange markers indicate unfavorable responses). Systemic therapies are marked by blue rectangles along the time bar that indicate duration of therapy. RUQ: Right upper quadrant; CR: Complete response; SD: Stable disease; PD: Progressing disease; met: Metastasis; FDG: Fluorodeoxyglucose; PET: Positron emission tomography; ctDNA: Circulating tumor DNA; Y-90: Yttrium-90; PACC: Pancreatic acinar cell carcinoma.
- Citation: Skorupan N, Sperling D, Nutting C, Miettinen M, Cohn A, Alewine C. Use of yttrium-90 radioembolization to control liver metastases in pancreatic acinar cell carcinoma and pancreatoblastoma: Two case reports. World J Gastroenterol 2026; 32(8): 113861
- URL: https://www.wjgnet.com/1007-9327/full/v32/i8/113861.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i8.113861